Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma (Nasdaq:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has announced its participation in two upcoming investor conferences in September 2025.

Management will present at the MicroCap Rodeo Fall Conference in New York City on September 25, 2025, at 2:00 PM ET, and at the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025, at 2:45 PM ET. Both presentations will be available via webcast, and management will conduct one-on-one meetings during both events.

Aytu BioPharma (NASDAQ:AYTU) reported its fiscal 2025 results with net revenue of $66.4 million, a 2% increase from fiscal 2024. The company posted a net loss of $13.6 million and adjusted EBITDA of $9.2 million, with a strong cash position of $31.0 million as of June 30, 2025.

The company's ADHD Portfolio generated $57.6 million in revenue, while the Pediatric Portfolio contributed $8.8 million. A significant highlight is Aytu's exclusive agreement to commercialize EXXUA, a novel first-in-class treatment for major depressive disorder (MDD), with launch planned for Q4 2025 targeting the $22 billion U.S. MDD market.

Aytu BioPharma (NASDAQ:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has scheduled its fiscal 2025 full year and fourth quarter financial results announcement for September 23, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. Eastern time on the same day, featuring a results review and Q&A session. The call will be accessible via phone and webcast, with replay available until October 7, 2025.

Aytu BioPharma (Nasdaq:AYTU) has appointed Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs, effective June 30, 2025. Dr. Westfield, a former Aytu executive and Nobel Prize contributor, will oversee medical and scientific affairs strategies, focusing on the commercial launch of EXXUA™.

EXXUA, a novel FDA-approved treatment for major depressive disorder (MDD), is set to launch in Q4 2025. As the first-in-class selective serotonin 5HT1a receptor agonist, EXXUA will compete in the $22 billion U.S. prescription MDD market. Notably, it's the only serotonin-targeting antidepressant without sexual dysfunction warnings, and has been tested in over 5,000 patients.

Aytu BioPharma has expanded and extended its lending agreement with Eclipse Business Capital, strengthening its financial position ahead of EXXUA's commercial launch. The term loan maturity has been extended to June 2029, with the principal balance increased to $13.0 million from $11.1 million. The revolving credit facility has been expanded by $1.5 million. This follows Aytu's recent exclusive agreement to commercialize EXXUA, a first-in-class antidepressant for major depressive disorder, in the U.S. market worth over $22 billion. EXXUA has shown promising results in clinical trials with over 5,000 patients, demonstrating significant improvement in depression symptoms with sexual side effects comparable to placebo. The company recently closed a $16.6 million public offering and plans to launch EXXUA in Q4 2025.

Aytu BioPharma has closed an upsized at-the-market public offering, raising $16.6 million in gross proceeds through the sale of common stock and prefunded warrants. The offering was led by healthcare-focused institutional investors including Nantahala Capital Management and Stonepine Capital Management. The funds will support the commercialization of EXXUA, a first-in-class FDA-approved antidepressant for Major Depressive Disorder (MDD). EXXUA, a selective serotonin 5HT1a receptor agonist, has shown significant improvement in depression symptoms across 5,000+ patient trials with sexual side effects comparable to placebo. Unlike SSRIs, EXXUA has no reuptake inhibition activity and shows no significant adverse effects on weight, blood pressure, heart rate, or liver function. The company plans to launch EXXUA in Q4 2025, targeting the $22 billion US prescription MDD market.

Aytu BioPharma (NASDAQ:AYTU) has announced the pricing of an upsized public offering of 9.6 million shares of common stock at $1.50 per share, with potential for an additional 1.44 million shares through a 30-day underwriter option. The offering, led by Nantahala Capital Management and Stonepine Capital Management, is expected to raise approximately $14.4 million in gross proceeds. The company plans to use the funds for general corporate purposes, working capital, and to secure exclusive commercialization rights for EXXUA, an FDA-approved treatment for major depressive disorder. Lake Street Capital Markets is acting as sole book runner, with Maxim Group as lead manager. The offering is expected to close around June 9, 2025.

Aytu BioPharma (NASDAQ:AYTU) has secured exclusive rights to commercialize EXXUA (gepirone), a first-in-class antidepressant, in the United States. EXXUA is a novel selective serotonin 5HT1a receptor agonist FDA-approved for treating Major Depressive Disorder (MDD) in adults. The drug has shown significant efficacy in clinical trials involving over 5,000 patients and notably demonstrates sexual side effects comparable to placebo. EXXUA will compete in the $22 billion US prescription MDD market, with launch expected in Q4 2025. The deal is financed by healthcare-focused investors including Nantahala Capital Management and Stonepine Capital Management. Unlike SSRIs, EXXUA has no reuptake inhibition activity and shows no significant adverse effects on weight, blood pressure, heart rate, or liver function. The agreement includes an upfront payment, fixed payment at one-year post-launch, royalties on net revenue, and performance-based milestone payments.

Aytu BioPharma (NASDAQ:AYTU) reported strong financial results for Q3 FY2025. The company achieved total net revenue of $18.5 million, up 32% year-over-year, driven by growth in both ADHD and Pediatric portfolios. The ADHD Portfolio revenue increased 25% to $15.4 million, while the Pediatric Portfolio saw a 77% increase to $3.1 million. The company reported net income of $4.0 million ($0.65 basic and $0.21 diluted EPS), compared to a net loss in Q3 FY2024. Adjusted EBITDA improved to $3.9 million from $0.9 million year-over-year. Cash position stood at $18.2 million, with the company reducing long-term debt by $2.5 million during the quarter. Gross profit was $12.8 million (69% margin), slightly down from 74% in the previous year due to temporary manufacturing transition costs.